Cell therapy weekly: European Commission approves the first anti-BCMA CAR-T therapy for multiple myeloma

This week: Abecma (idecabtagene vicleucel; ide-cel) has been approved by the European Commission for relapsed and refractory multiple myeloma, Lonza’s Cocoon® Platform shows successful clinical outcomes in patients treated with CAR-T immunotherapy, and preclinical results of IASO Biotherapeutics’ proprietary next-generation CAR-T therapy, CT125A, were recently published. The news highlights: European Commission approves the first anti-BCMA CAR-T therapy for multiple myeloma Cocoon® Platform shows successful clinical outcomes in patients treated with CAR-T immunotherapy CD5-targeting CAR-T therapy: preclinical results published for T-cell hematologic malignancies   European Commission approves the first anti-BCMA CAR-T therapy for multiple myeloma Bristol Myers Squibb (NJ, USA) has...